ImmunityBio/$IBRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmunityBio
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Ticker
$IBRX
Sector
Primary listing
Employees
685
Headquarters
Website
ImmunityBio Metrics
BasicAdvanced
$2.4B
-
-$0.49
-0.07
-
Price and volume
Market cap
$2.4B
Beta
-0.07
52-week high
$5.66
52-week low
$1.83
Average daily volume
10M
Financial strength
Current ratio
4.11
Quick ratio
3.475
Long term debt to equity
-146.577
Total debt to equity
-147.883
Interest coverage (TTM)
-2.10%
Profitability
EBITDA (TTM)
-269.066
Gross margin (TTM)
99.66%
Net profit margin (TTM)
-648.57%
Operating margin (TTM)
-504.18%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-42.14%
Return on equity (TTM)
57.95%
Valuation
Price to revenue (TTM)
34.596
Price to book
-3.96
Price to tangible book (TTM)
-3.86
Price to free cash flow (TTM)
-5.49
Free cash flow yield (TTM)
-18.21%
Free cash flow per share (TTM)
-0.45
Growth
Revenue change (TTM)
4,227.22%
Earnings per share change (TTM)
-48.57%
3-year revenue growth (CAGR)
382.14%
3-year earnings per share growth (CAGR)
-19.83%
What the Analysts think about ImmunityBio
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
ImmunityBio Financial Performance
Revenues and expenses
ImmunityBio Earnings Performance
Company profitability
ImmunityBio News
AllArticlesVideos
Biotech Breakouts: 3 Stocks With Massive Upside Potential
MarketBeat1 month ago
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
Business Wire2 months ago
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmunityBio stock?
ImmunityBio (IBRX) has a market cap of $2.4B as of October 26, 2025.
What is the P/E ratio for ImmunityBio stock?
The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of October 26, 2025.
Does ImmunityBio stock pay dividends?
No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next ImmunityBio dividend payment date?
ImmunityBio (IBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunityBio?
ImmunityBio (IBRX) has a beta rating of -0.07. This means that it has an inverse relation to market volatility.